Claude

Know the Business

Cigna Group is a pharmacy-services company that happens to also insure people. Roughly 85% of revenue flows through Evernorth Health Services, a PBM and specialty pharmacy platform, while Cigna Healthcare provides employer medical benefits at thin margins. The market often prices CI as a health insurer, but the real economic engine is drug distribution and rebate intermediation – a high-throughput, low-margin-per-claim business where scale and contract retention determine everything. The single biggest risk the market may be underestimating is the structural margin compression from the transition to a rebate-free pharmacy model beginning in 2027-2028.

How This Business Actually Works

Cigna Group operates two economically distinct businesses under one roof.

Evernorth Health Services (~$235B in 2025 adjusted revenue, ~73% of pre-tax adjusted operating income) is the drug supply chain. Express Scripts adjudicates pharmacy claims for health plans, employers, and government programs. It earns money three ways: (1) the spread between what it pays pharmacies and what it charges plan sponsors, (2) fees for administering benefit programs, and (3) a share of rebates negotiated with drug manufacturers. Accredo, the specialty pharmacy, and CuraScript, the specialty distributor, add higher-margin volume. This business processes ~2.2 billion adjusted claims per year.

Cigna Healthcare (~$47B in 2025 adjusted revenue, ~27% of pre-tax adjusted operating income) underwrites and administers employer medical benefits. About 79% of medical customers are in self-funded ASO arrangements where CI earns administrative fees but does not bear claims risk. The remaining 21% are insured (guaranteed cost or experience-rated), where CI takes premium and pays claims.

The analogy: Evernorth is a toll road for prescription drugs – massive volume, thin per-unit economics, nearly impossible to displace once embedded in a plan sponsor's workflow. Cigna Healthcare is the adjacent insurance operation that feeds Evernorth captive volume and earns modest underwriting margins.

The critical detail: Evernorth's revenue grew 53% in two years while Cigna Healthcare's shrank 8%, largely due to the Medicare Advantage divestiture to HCSC for $4.9B in March 2025. CI is deliberately concentrating on drug distribution and services over insurance risk.

Cost structure: Pharmacy and service costs ($215B) are ~78% of total revenue and largely pass-through – drug costs flow in and out. Medical costs ($34.3B) represent the insured risk exposure. SG&A ($14.6B) is the controllable overhead at ~5.3% of revenue, declining as a ratio. The economic surplus comes from negotiating better drug prices than what clients pay, managing specialty pharmacy margins, and earning fees on a growing base of administered claims.

The Playing Field

Cigna competes in two overlapping arenas: PBM/pharmacy services (against CVS Caremark and UnitedHealth/Optum Rx) and health benefits (against UnitedHealthcare, Elevance, Humana, and Centene). The peer set reveals that CI's differentiation lies in the PBM-first model.

What the peer set reveals:

• CI has the highest ROE in the group at 15.1% despite thin net margins, because of massive leverage through its balance sheet ($31.5B in debt, $45B in goodwill from the Express Scripts acquisition). This is a capital-structure-driven return, not an operating superiority.
• Elevance (ELV) is the best pure-play health insurer – higher net margins than CI with cleaner operating economics. ELV is what Cigna Healthcare would look like as a standalone.
• CVS and Centene are struggling. CVS's Aetna acquisition has delivered sub-3% ROE. Centene posted a net loss in 2025. These are cautionary tales about integration complexity.
• UNH is the standard. It runs the largest integrated health services platform (Optum + UnitedHealthcare) and earns 2.7% net margins on $448B in revenue. CI's Evernorth is the closest structural peer to Optum, but UNH trades at nearly 2x CI's P/E, reflecting the market's trust in UNH's execution and diversification.

Is This Business Cyclical?

This business has low economic cyclicality but high regulatory and political cyclicality. Drug utilization and employer health coverage are relatively recession-resistant – people take medications regardless of GDP growth, and employer-sponsored coverage is sticky.

Key observations:

• Revenue never declined, even through COVID-19 (FY2020). The jump from FY2023 to FY2024 (+$52B) reflects Evernorth contract wins, not organic medical growth.
• Operating income has been remarkably stable at $8-9.5B, varying less than 15% peak-to-trough over seven years. This is a spread business, not a volume-sensitive manufacturer.
• Net income is volatile due to one-time items (FY2020 gains, FY2024 VillageMD impairment), not operating weakness. Adjusted EPS tells a cleaner story: $25.09 (2023) -> $27.33 (2024) -> $29.84 (2025), growing at a steady ~9% annually.
• The real cycle risk is political. PBM regulation, drug pricing reform, FTC scrutiny of rebate practices, and Medicare/Medicaid rate changes hit margins unpredictably. The 2025 Medicare Advantage divestiture was partly a response to deteriorating government program economics.

The Metrics That Actually Matter

Why these five metrics matter more than surface ratios:

1. Medical Care Ratio – the single most important number for Cigna Healthcare's insured book. It has risen 310 bps in two years. When MCR exceeds ~85%, insured margins compress toward zero. CI is managing this by shedding Medicare Advantage and focusing on employer business, but the IFP book drove deterioration in 2025.

2. Evernorth Pre-Tax Margin – declining from 4.2% to 3.1% over two years despite revenue growing 53%. This is the biggest strategic tension: CI is investing in rebate-free models, new specialty pharmacy capacity, and client onboarding, all of which compress near-term margins. If margin stabilizes at 3%+, the business works. If it drifts below 2.5%, the Express Scripts acquisition thesis weakens.

3. Adjusted EPS – strips out VillageMD write-downs, amortization of Express Scripts intangibles, and restructuring charges. This is the metric management steers toward and the one that drives buyback math. 9% annualized growth is credible.

4. Pharmacy Claim Volume – the tonnage metric. More claims = more bargaining power with pharmacies and manufacturers = better unit economics. Volume grew 40% in two years, largely from Centene and Prime onboarding.

5. Free Cash Flow – $8.4B in 2025 on a $74B market cap = ~11% FCF yield. This is the cheapness argument. Even with FCF declining from the 2023 peak, CI generates enough cash to fund $5-6B in annual buybacks and dividends while carrying $31B in debt.

The gap between FCF and dividends is deployed into share buybacks. Outstanding shares fell from ~299M (2022) to ~263M (2025), a 12% reduction in three years. This is the primary EPS growth engine alongside organic operating growth.

What I'd Tell a Young Analyst

Watch the Evernorth margin, not the headline revenue. Revenue growth in drug distribution is mechanically high because drug prices keep rising and client onboarding inflates the top line. What matters is whether CI retains its share of the spread. The rebate-free model transition (2027-2028) will temporarily depress margins – the question is whether transparency attracts enough new clients to offset it.

The Express Scripts goodwill ($45B) is the elephant. This represents 29% of total assets and exceeds total equity. CI paid $67B for Express Scripts in 2018. If PBM economics permanently deteriorate, impairment risk is real. But the business has generated $50B+ in cumulative operating cash flow since the acquisition, so the cash-on-cash return has been strong.

Ignore GAAP net income in any given year. The VillageMD impairment ($2.7B in 2024), the HCSC sale gain/loss, deferred tax charges, and amortization of Express Scripts intangibles make GAAP earnings a terrible signal. Adjusted EPS and FCF tell the truth.

The moat is real but narrowing. CI's PBM scale (2.2B claims), specialty pharmacy network (Accredo), and long-term client contracts create genuine switching costs. But Amazon Pharmacy, Mark Cuban's Cost Plus model, and state-level PBM regulation are eroding the rebate-intermediation value proposition. CI's move to rebate-free pricing is a defensive acknowledgment that the old model's days are numbered.

What would change the thesis: (1) Loss of Centene contract at renewal (currently extended through end of decade – low probability near-term but existential-level concentration risk); (2) Federal legislation that bans PBM spread pricing or mandates full rebate pass-through; (3) Sustained MCR above 87% forcing exit from insured employer business; (4) Evernorth margin falling below 2.5% indicating the scale economics no longer work.

At 8.9x forward earnings and an ~11% FCF yield, CI is priced for mediocrity. The business is better than that, but the market is right to worry about the structural transition in pharmacy services economics.